Sfoglia per Autore
The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma
2003 M. Iavarone, P. Lampertico, C. Seletti, M.F. Donato, G. Ronchi, E. Del Ninno, M. Colombo
A prospective study of peripheral blood alpha-fetoprotein messenger RNA in cirrhotic patients at risk of hepatocellular carcinoma
2003 M. Iavarone, P. Lampertico, G. Ronchi, E. Del Ninno, A. Zanella, M. Colombo
Assessing tumor angiogenesis : Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells
2004 C. Rabascio, E. Muratori, P. Mancuso, A. Calleri, V. Raia, T. Foutz, S. Cinieri, G. Veronesi, G. Pruneri, P. Lampertico, M.A. Iavarone, G. Martinelli, A. Goldhirsch, F. Bertolini
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
2004 V. Di Marco, A. Marzano, P. Lampertico, P. Andreone, T. Santantonio, P.L. Almasio, M. Rizzetto, A. Craxì, G. Raimondo, G. Squadrito, A. Spadaro, O. Ferrah, T. Santantonio, G. Pastore, G. Niro, A. Andriulli, G. Stornaiolo, M. Stanzione, G.B. Gaeta, F. Piccinino, A. Marrone, G. Ruggiero, R. Ganga, M. Bernas coni, G. Pilleri, M. Brunetto, B. Coco, F. Bonino, G. Mazzella, F. Lodato, P. Andreone, C. Cursaro, s. Fiorino, A.G. Gramenzi, M. Massari, F. Torre, M. Basso, A. Picciotto, S. Targhetta, P. Burra, V. Ciappina, E. Mazzeffini, R. Bruno, S. Bruno, M. Vigano, M. Iavarone, E. Del Ninno, M. Colombo, A. Casella, M. Sonzogni, G. Colloredo, S. Rossi, M. Puoti, S. Gaia, V. Barbon, M. Lagget
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma
2005 P. Lampertico, M. Vigano, E. Manenti, M.A. Iavarone, G. Lunghi, M. Colombo
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B
2005 P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M.A. Iavarone, E. Del Ninno, M. Colombo
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B
2005 P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M.A. Iavarone, E. Del Ninno, M. Colombo
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy
2005 P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M.A. Iavarone, G. Colucci, M. Colombo
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy
2005 P. Lampertico, M. Viganò, E. Manenti, G. Lunghi, M.A. Iavarone, G. Colucci, M. Colombo
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy
2005 M. Viganò, A. Aghemo, M. Iavarone, P. Lampertico, M. Rumi, A. Sangiovanni, E. Del Ninno, M. Colombo
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine
2005 P. Lampertico, M. Viganò, E. Manenti, M.A. Iavarone, G. Lunghi, M. Colombo
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years
2006 P. Lampertico, M. Viganò, M. Iavarone, E. Manenti, G. Lunghi, E. Del Ninno, M. Colombo
Global Antiviral Journal “Bridging the Sciencies, HIV, HBV, HCV and Emerging Viruses”
2006 M. Colombo, M. Iavarone
Local circulation of VEGF is involved in collateral vessels development in cirrhotic patients with portal hypertension
2006 M. Iavarone, F. Iannuzzi, E. Manenti, F. Fabris, A. Dell'Era, G. Petazzi, M. Primignani, R. De Franchis, M. Colombo
Serum expression of lectin reactive alphafetoprotein, des-gamma-carboxy prothrombin, Golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma
2007 A. Sangiovanni, R. Romeo, G.M. Prati, A. Manini, M. Iavarone, G. Ronchi, M. Colombo
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis
2007 M. Iavarone, P. Lampertico, M. Viganò, E. Del Ninno, R. de Franchis, M. Colombo
Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients
2007 A. Sangiovanni, M. Viganò, M. Iavarone, A. Aghemo, B. Cesana, G.M. Prati, M.A. Manini, R. Romeo, M. Colombo
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleos(t)ide analogues
2007 M. Viganò, P. Lampertico, M. Iavarone, A. Sangiovanni, E. Del Ninno, M. Colombo
Six years of on demand LAM +/- ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with hbeag-negative cirrhosis
2007 M. Iavarone, P. Lampertico, M. Viganò, E. Del Ninno, R. de Franchis, M. Colombo
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients
2007 P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, G. Lunghi, E. Del Ninno, M. Colombo
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile